Evolus, Inc. (EOLS): Cash & Equivalents
$53.83M
As of 2025-12-31
$45.17M
As of 2026-06-30
-0.1%
3-year compound annual growth
-12.1%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $53.83M | -38.1% | 2026-03-03, Balance as of period end |
| 2024-12-31 | $86.95M | +38.4% | 2026-03-03, Balance as of period end |
| 2023-12-31 | $62.84M | +16.5% | 2025-03-04, Balance as of period end |
| 2022-12-31 | $53.92M | -63.1% | 2024-03-07, Balance as of period end |
| 2021-12-31 | $146.26M | +42.6% | 2023-03-08, Balance as of period end |
| 2020-12-31 | $102.56M | -6.7% | 2022-03-03, Balance as of period end |
| 2019-12-31 | $109.89M | +18.0% | 2021-03-25, Balance as of period end |
| 2018-12-31 | $93.16M | n/a | 2020-02-25, Balance as of period end |
| 2017-12-31 | $0 | n/a | 2019-03-20, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Evolus, Inc. (EOLS) | 2025-12-31 | $53.83M | -38.1% |
| Ironwood Pharmaceuticals Inc (IRWD) | 2025-12-31 | $215.46M | +143.3% |
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $111.04M | +55.0% |
| CorMedix Inc. (CRMD) | 2025-12-31 | $144.84M | +256.3% |
| Harrow, Inc. (HROW) | 2025-12-31 | $72.93M | +54.4% |
| Ligand Pharmaceuticals Inc (LGND) | 2025-12-31 | $174.93M | +141.9% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | $142.90M | +42.2% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $230.52M | +56.5% |
| MannKind Corp (MNKD) | 2025-12-31 | $74.88M | +61.6% |
Compare EOLS, IRWD, XERS, CRMD side by side · Screen every company in Pharmaceutical Preparations ↗